Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated neuroprotective effects and hold potential advantages in enhancing cognitive function. This study aimed to clarify the association between SGLT2 inhibitors and the risk of dementia among individuals diagnosed with type 2 diabetes (T2D). Methods: All cohort studies concerning the impact of SGLT2 inhibitors on dementia onset in patients with T2D were identified. The literature search encompassed PubMed, Embase, Cochrane Library, and Web of Science from establishment to March 2024, with no language restriction. The quality of the literature was evaluated using the Newcastle-Ottawa Scale (NOS). Meta-analysis was conducted using RevMan 5.4 software, calculating pooled risk ratio (RR) with 95% confidence intervals (CIs) for dichotomous outcomes. Results: Five cohort studies encompassing a total of 331,908 patients were included in the analysis. The findings showed that individuals receiving SGLT2 inhibitors had a lower risk of dementia (I2 = 42%, p = 0.14; RR: 0.77; 95% CI: 0.71–0.84) compared to the control group. Subgroup analyses confirmed the consistent beneficial effects of SGLT2 inhibitors across different study regions (I2 = 0%, p = 0.60) and genders (I2 = 0%, p = 0.50). Conclusions: SGLT2 inhibitors may reduce the dementia risk in T2D patients. Given the limitations of the study, further investigations were warranted to confirm the benefits.

1.
Ferrannini
E
.
Sodium-glucose Co-transporters and their inhibition: clinical physiology
.
Cell Metab
.
2017
;
26
(
1
):
27
38
.
2.
Jayarathne
HSM
,
Debarba
LK
,
Jaboro
JJ
,
Ginsburg
BC
,
Miller
RA
,
Sadagurski
M
.
Neuroprotective effects of Canagliflozin: lessons from aged genetically diverse UM-HET3 mice
.
Aging Cell
.
2022
;
21
(
7
):
e13653
.
3.
Millar
P
,
Pathak
N
,
Parthsarathy
V
,
Bjourson
AJ
,
O’Kane
M
,
Pathak
V
, et al
.
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice
.
J Endocrinol
.
2017
;
234
(
3
):
255
67
.
4.
Atiya
A
,
Das Gupta
D
,
Alsayari
A
,
Alrouji
M
,
Alotaibi
A
,
Sharaf
SE
, et al
.
Linagliptin and empagliflozin inhibit microtubule affinity regulatory kinase 4: repurposing anti-diabetic drugs in neurodegenerative disorders using in silico and in vitro approaches
.
ACS Omega
.
2023
;
8
(
7
):
6423
30
.
5.
Samman
WA
,
Selim
SM
,
El Fayoumi
HM
,
El-Sayed
NM
,
Mehanna
ET
,
Hazem
RM
.
Dapagliflozin ameliorates cognitive impairment in aluminum-chloride-induced Alzheimer's disease via modulation of AMPK/mTOR, oxidative stress and glucose metabolism
.
Pharmaceuticals
.
2023
:
16
(
5
):
753
.
6.
Sim
AY
,
Choi
DH
,
Kim
JY
,
Kim
ER
,
Goh
AR
,
Lee
YH
, et al
.
SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model
.
J Biomed Pharmacother
.
2023
;
168
:
115755
.
7.
Bohlken
J
,
Jacob
L
,
Kostev
K
.
Association between the use of antihyperglycemic drugs and dementia risk: a case-control study
.
J Alzheimers Dis
.
2018
;
66
(
2
):
725
32
.
8.
Wium-Andersen
IK
,
Osler
M
,
Jørgensen
MB
,
Rungby
J
,
Wium-Andersen
MK
.
Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study
.
Eur J Endocrinol
.
2019
;
181
(
5
):
499
507
.
9.
Zhou
JB
,
Tang
X
,
Han
M
,
Yang
J
,
Simó
R
.
Impact of antidiabetic agents on dementia risk: a Bayesian network meta-analysis
.
Metabolism
.
2020
;
109
:
154265
.
10.
Tang
H
,
Shao
H
,
Shaaban
CE
,
Yang
K
,
Brown
J
,
Anton
S
, et al
.
Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies
.
J Am Geriatr Soc
.
2023
;
71
(
7
):
2096
106
.
11.
Moher
D
,
Liberati
A
,
Tetzlaff
J
,
Altman
DG
;
PRISMA Group
.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
.
Ann Intern Med
.
2009
;
151
(
4
):
264
W64
.
12.
Counsell
C
.
Formulating questions and locating primary studies for inclusion in systematic reviews
.
Ann Intern Med
.
1997
;
127
(
5
):
380
7
.
13.
Richardson
WS
,
Wilson
MC
,
Nishikawa
J
,
Hayward
RS
.
The well-built clinical question: a key to evidence-based decisions
.
ACP J Club
.
1995
;
123
(
3
):
A12
3
.
14.
Cumpston
M
,
Li
T
,
Page
MJ
,
Chandler
J
,
Welch
VA
,
Higgins
JP
, et al
.
Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions
.
J Cochrane Database Syst Rev
.
2019
;
10
(
10
):
Ed000142
.
15.
Stang
A
.
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
.
Eur J Epidemiol
.
2010
;
25
(
9
):
603
5
.
16.
Kussainova
A
,
Kassym
L
,
Akhmetova
A
,
Glushkova
N
,
Sabirov
U
,
Adilgozhina
S
, et al
.
Vitiligo and anxiety: a systematic review and meta-analysis
.
PLoS One
.
2020
;
15
(
11
):
e0241445
.
17.
Cumpston
M
,
Li
T
,
Page
MJ
,
Chandler
J
,
Welch
VA
,
Higgins
JP
, et al
.
Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions
.
Cochrane Database Syst Rev
.
2019
;
10
(
10
):
ED000142
.
18.
Higgins
JP
,
Thompson
SG
.
Quantifying heterogeneity in a meta-analysis
.
Stat Med
.
2002
;
21
(
11
):
1539
58
.
19.
Begg
CB
,
Mazumdar
M
.
Operating characteristics of a rank correlation test for publication bias
.
Biometrics
.
1994
;
50
(
4
):
1088
101
.
20.
Mui
JV
,
Zhou
J
,
Lee
S
,
Leung
KSK
,
Lee
TTL
,
Chou
OHI
, et al
.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. Dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis
.
Front Cardiovasc Med
.
2021
;
8
:
747620
.
21.
Siao
WZ
,
Lin
TK
,
Huang
JY
,
Tsai
CF
,
Jong
GP
.
The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study
.
Diab Vasc Dis Res
.
2022
;
19
(
3
):
14791641221098168
.
22.
Proietti
R
,
Rivera-Caravaca
JM
,
López-Gálvez
R
,
Harrison
SL
,
Marín
F
,
Underhill
P
, et al
.
Cerebrovascular, cognitive and cardiac benefits of SGLT2 inhibitors therapy in patients with atrial fibrillation and type 2 diabetes mellitus: results from a global federated health network analysis
.
J Clin Med
.
2023
;
12
(
8
):
2814
.
23.
Wu
CY
,
Iskander
C
,
Wang
C
,
Xiong
LY
,
Shah
BR
,
Edwards
JD
, et al
.
Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study
.
Diabetes Care
.
2023
;
46
:
297
304
.
24.
Chen
YY
,
Chang
HC
,
Lin
YJ
,
Chien
KL
,
Hsieh
YC
,
Chung
FP
, et al
.
The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation
.
Diabetes Metab Res Rev
.
2024
;
40
(
2
):
e3775
.
25.
Organization WH
. Global status report on the public health response to dementia. J.
2021
.
26.
Gudala
K
,
Bansal
D
,
Schifano
F
,
Bhansali
A
.
Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies
.
J Diabetes Investig
.
2013
;
4
(
6
):
640
50
.
27.
Chatterjee
S
,
Peters
SA
,
Woodward
M
,
Mejia Arango
S
,
Batty
GD
,
Beckett
N
, et al
.
Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia
.
Diabetes Care
.
2016
;
39
:
300
7
.
28.
Zhang
J
,
Chen
C
,
Hua
S
,
Liao
H
,
Wang
M
,
Xiong
Y
, et al
.
An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease
.
Diabetes Res Clin Pract
.
2017
;
124
:
41
7
.
29.
Weinberg
SR
,
Segev
O
,
Dor
S
,
Raz
I
.
Drug therapies for diabetes
.
Int J Mol Sci
.
2023
;
24
(
24
):
17147
.
30.
Hayden
MR
,
Grant
DG
,
Aroor
AR
,
DeMarco
VG
.
Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db/db mouse
.
Brain Sci
.
2019
;
9
(
3
):
57
.
31.
Hierro-Bujalance
C
,
Infante-Garcia
C
,
Del Marco
A
,
Herrera
M
,
Carranza-Naval
MJ
,
Suarez
J
, et al
.
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes
.
Alzheimers Res Ther
.
2020
;
12
(
1
):
40
.
32.
Lajara
R
.
The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
.
Expert Opin Pharmacother
.
2014
;
15
(
17
):
2565
85
.
33.
D’Andrea
E
,
Wexler
DJ
,
Kim
SC
,
Paik
JM
,
Alt
E
,
Patorno
E
.
Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels
.
J JAMA Intern Med
.
2023
;
1833
:
242
54
.
34.
Yoshikawa
T
,
Kishi
T
,
Shinohara
K
,
Takesue
K
,
Shibata
R
,
Sonoda
N
, et al
.
Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats
.
Hypertens Res
.
2017
;
40
(
7
):
646
51
.
35.
Pandey
J
,
Tamrakar
AK
.
SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
.
Expert Opin Ther Pat
.
2019
;
29
(
5
):
369
84
.
36.
Pruett
JE
,
Everman
SJ
,
Hoang
NH
,
Salau
F
,
Taylor
LC
,
Edwards
KS
, et al
.
Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition
.
Biol Sex Differ
.
2022
;
13
(
1
):
45
.
37.
Rizzo
MR
,
Di Meo
I
,
Polito
R
,
Auriemma
MC
,
Gambardella
A
,
di Mauro
G
, et al
.
Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment
.
Pharmacol Res
.
2022
;
176
:
106062
.
38.
Guo
H
,
Yu
X
,
Liu
Y
,
Paik
DT
,
Justesen
JM
,
Chandy
M
, et al
.
SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant
.
Sci Transl Med
.
2023
;
15
(
680
):
eabp9952
.
39.
Scisciola
L
,
Olivieri
F
,
Ambrosino
C
,
Barbieri
M
,
Rizzo
MR
,
Paolisso
G
.
On the wake of metformin: do anti-diabetic SGLT2 inhibitors exert anti-aging effects
.
Ageing Res Rev
.
2023
;
92
:
102131
.
40.
Liu
Z
,
Ma
X
,
Ilyas
I
,
Zheng
X
,
Luo
S
,
Little
PJ
, et al
.
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
.
Theranostics
.
2021
;
11
(
9
):
4502
15
.
41.
Bathina
S
,
Das
UN
.
Brain-derived neurotrophic factor and its clinical implications
.
Arch Med Sci
.
2015
;
11
(
6
):
1164
78
.
42.
Han
R
,
Liu
Z
,
Sun
N
,
Liu
S
,
Li
L
,
Shen
Y
, et al
.
BDNF alleviates neuroinflammation in the Hippocampus of type 1 diabetic mice via blocking the aberrant HMGB1/RAGE/NF-κB pathway
.
Aging Dis
.
2019
;
10
(
3
):
611
25
.
43.
Mone
P
,
Lombardi
A
,
Gambardella
J
,
Pansini
A
,
Macina
G
,
Morgante
M
, et al
.
Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction
.
Diabetes Care
.
2022
;
45
(
5
):
1247
51
.
44.
Cao
Q
,
Tan
CC
,
Xu
W
,
Hu
H
,
Cao
XP
,
Dong
Q
, et al
.
The prevalence of dementia: a systematic review and meta-analysis
.
J Alzheimers Dis
.
2020
;
73
(
3
):
1157
66
.
45.
Wilbur
J
.
Dementia: dementia types
.
FP Essent
.
2023
;
534
:
7
11
.
46.
Washburn
WN
,
Poucher
SM
.
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
.
Expert Opin Investig Drugs
.
2013
;
22
(
4
):
463
86
.
47.
Gallo
LA
,
Wright
EM
,
Vallon
V
.
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
.
Diab Vasc Dis Res
.
2015
;
12
(
2
):
78
89
.
48.
Zinman
B
,
Wanner
C
,
Lachin
JM
,
Fitchett
D
,
Bluhmki
E
,
Hantel
S
, et al
.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
.
N Engl J Med
.
2015
;
373
(
22
):
2117
28
.
49.
Neal
B
,
Perkovic
V
,
Mahaffey
KW
,
de Zeeuw
D
,
Fulcher
G
,
Erondu
N
, et al
.
Canagliflozin and cardiovascular and renal events in type 2 diabetes
.
N Engl J Med
.
2017
;
377
(
7
):
644
57
.
50.
Wiviott
SD
,
Raz
I
,
Bonaca
MP
,
Mosenzon
O
,
Kato
ET
,
Cahn
A
, et al
.
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
.
N Engl J Med
.
2019
;
380
(
4
):
347
57
.
You do not currently have access to this content.